Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NOTA-AocNle-CycMSHhex
- Development stage
- Unknown
- Lead developer
- University of Colorado Denver
- Modality
- Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
01
Overview
64Cu-NOTA-AocNle-CycMSHhex: sourced facts only. name: "64Cu-NOTA-PEG2Nle-CycMSHhex and 64Cu-NOTA-AocNle-CycMSHhex were readily prepared with more than 90% radiolabeling yields and showed MC1R-specific binding on B16/F10 cells." [PMID:35486894]; target: "64Cu-NOTA-PEG2Nle-CycMSHhex and 64Cu-NOTA-AocNle-CycMSHhex were readily prepared with more than 90% radiolabeling yields and showed MC1R-specific binding on B16/F10 cells." [PMID:35486894]; developer: "Department of Radiology, University of Colorado Denver, Aurora, Colorado 80045, United States." [PMID:35486894]
02
Targets
MC1R (Melanocortin Type 1 Receptor)
Beyond the preview
Go deeper on 64Cu-NOTA-AocNle-CycMSHhex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-NOTA-AocNle-CycMSHhex.